Your search history is turned on.
Date: April 30, 2024 Jurisdictions: Ontario
Create a report of distributions outside Canada Form 72-503F FORM 72-503F REPORT OF DISTRIBUTIONS OUTSIDE CANADA 1. Full name, address and telephone number of the Issuer. a) Full name of issuer Medicenna Therapeutics Corp. / Medicenna Therapeutics Corp. b) Head office address Street address 2 Bloor St W., 7th Floor Province/State Ontario Municipality Toro...
Date: April 30, 2024 Jurisdictions: Alberta, British Columbia, Ontario
20240430_Wt_Cert PRE-FUNDED COMMON SHARE PURCHASE WARRANT Medicenna Therapeutics Corp. Warrant Certificate No.: 2024-PFW-01 Number of Common Shares Purchasable: 5,141,388 Date: April 30, 2024 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT CERTIFICATE (the Pre-Funded Warrant) certifies that, for ...
20240430_MCR FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Medicenna Therapeutics Corp. (the Company) 2 Bloor Street West, 7th Floor Toronto, Ontario M4W 3E2 2. Date of Material Changes April 26, 2024 3. News Releases A news release with respect to the material ...
20240430_PR 1 Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 Medicenna Therapeutics Corp. (Medicenna or the Com...
Date: April 26, 2024 Jurisdictions: Alberta, British Columbia, Ontario
20240426_PR 1 Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024 Medicenna Therapeutics Corp. (Medicenna or the Company) (TSX: MDNA) (M...
Date: April 24, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting Oral presentation of MDNA11s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity matched external control arm will also be presented as a poster TORONTO and HOUS...
Date: April 9, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) 100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluabl...
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighting immune cells i...
Date: April 4, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Mayfair Gold Sets the Record Straight and Corrects Muddy Waters Misleading and Inaccurate Statements Reiterates Board and Management Commitment to Good Governance and Value Creation MATHESON, Ontario, April 04, 2024 -- Mayfair Gold Corp. (Mayfair or the Company) (TSX-V: MFG; OTCQB: MFGCF) today responded to a letter to shareholders (the "Letter") released by Muddy Waters Capital LLC (Muddy Wate...
Date: March 6, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting Pre-clinical data on Medicennas first-in-class Masked and Tumor Targeted Bifunctional Superkine, MDNA113, will also be presented at the Annual Meeting TORONTO and HOUSTON, March 06, 2024 -- Medicenna Therapeutics Corp. (Medicenna or the Company) (TSX: MDNA, ...